
Before Wedneday's quarterly report from Genmab was released, the biotech company had already upgraded its 2021 financial guidance for revenue and operating result.
Last week, the company decided to adjust its full-year guidance upward, with new estimated operating results of DKK 2.3-3.2bn (USD 354.7-493.5m) from a revised revenue of DKK 7.9-8.5bn (USD 1.2-1.3bn). The previous guidance estimated operating results of DKK 1.5-2.4bn (USD 231.2-369.9m) from a total predicted revenue of DKK 7.3-7.9bn (USD 1.1-1.2bn).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app